GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...

British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is producing ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

(Il Sole 24 Ore Radiocor) - Milano, 13 gen - The UK pharmaceutical company GSK said it has agreed to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.

GSK PLC on Monday said it has agreed to acquire Boston, Massachusetts-based IDRx Inc in a deal that will add to its " ... Subscribe now to see this Premium News article from Alliance News ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.